UVA researchers Dorian Rosen, left, and Alban Gaultier found last year that fluvoxamine may stop deadly sepsis inflammation, in which the immune response spirals out of control.

An antidepressant medication is being tested as a potential treatment for COVID-19 after University of Virginia School of Medicine researchers determined it may prevent dangerous overreactions by the immune system.

Researchers at the Washington University School of Medicine in St. Louis are launching a clinical trial to determine if the drug fluvoxamine can prevent “cytokine storms,” in which the body is flooded with immune cells called cytokines. This frenzied immune response can lead to life-threatening organ failure and has been a major concern in patients with severe COVID-19 infections.
to read this article inits entirety click here:UVA Research / covid 19